Post-Orchiectomy Tumor Marker Management

Introduction to Tumor Marker Monitoring

The European Society for Medical Oncology recommends that tumor markers (AFP, β-hCG, and LDH) should be requested at least 7 days after radical orchiectomy and repeated until normalization or plateau is reached 1, 2, 3, 4, 5

The American Society of Clinical Oncology suggests that initial measurement should be performed at least 7 days after orchiectomy to allow for adequate evaluation of the kinetics of elevated preoperative markers 3, 4, 5
The National Comprehensive Cancer Network recommends that markers should be monitored until complete normalization, considering the specific half-lives: β-hCG has a half-life of 1-3 days and AFP of 5-7 days 2
If markers were elevated preoperatively, they should be repeated serially until documentation of normalization, progression, or plateau 1, 2

The European Association of Urology recommends requesting AFP, β-hCG, and LDH in all patients, regardless of preoperative values, on the 7th day post-orchiectomy 1, 2, 3, 4
This measurement is critical for final staging and risk stratification according to the IGCCCG classification 1, 2, 6

If markers were normal preoperatively, one postoperative measurement is sufficient to confirm the absence of occult metastatic disease 3, 4
If markers were elevated preoperatively, they should be repeated every 1-2 weeks until normalization, documenting the appropriate decline kinetics 2
Inadequate decline or plateau indicates residual or metastatic disease (stage IS) and requires immediate systemic treatment 2

The timing of chemotherapy should be based on marker measurements taken immediately before administration (on the same day) in patients with metastatic disease 1, 6
This measurement is essential for IGCCCG classification, which determines prognosis and treatment intensity 1, 6

Not waiting for complete normalization of markers before initiating staging studies; CT scans of the chest, abdomen, and pelvis should be performed regardless of marker status to detect radiologically visible metastatic disease 1, 2, 6

The National Comprehensive Cancer Network recommends that α-fetoprotein (AFP) is the definitive marker to distinguish nonseminoma from seminoma, as seminoma cells do not produce AFP, while nonseminomatous cells do 7, 8, 9

AFP is produced exclusively by nonseminomatous germ cell tumor cells and is never elevated in pure seminoma, making it the definitive discriminating marker 7, 8, 9
Any elevation of AFP above normal range indicates the presence of nonseminomatous elements, even if the histology appears to be "pure seminoma" 8, 9
Pure seminomas are constantly AFP-negative, making this marker 100% specific for distinguishing tumor type 7
AFP has a half-life of 5-7 days, allowing for reliable monitoring 8, 9

Human Chorionic Gonadotropin (hCG) can be elevated in BOTH seminoma and nonseminoma, making it useless for distinguishing between them 7, 8, 9
Lactate Dehydrogenase (LDH) is a nonspecific marker that can be elevated in both seminoma and nonseminoma, and serves primarily as a prognostic marker rather than a diagnostic discriminator 8, 9, 10

The National Comprehensive Cancer Network recommends that all three standard markers (AFP, hCG, and LDH) should be measured before and after orchiectomy for complete staging, but only AFP provides histologic discrimination 7, 8, 9
If AFP is elevated, diagnose and treat as nonseminoma regardless of histology 8, 9
If AFP is normal with elevated hCG and/or LDH, it is consistent with either seminoma or nonseminoma, and requires histologic confirmation 7, 11